期刊
FRONTIERS IN PHYSIOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2021.700847
关键词
HDL; Alzheimer's disease; APOE; ApoA-I; vascuar; imaging
类别
资金
- National Institute on Aging [R21AG056518, R01AG055770, R01AG054434, R01AG067063]
- National Institutes of Health [P50AG05142]
High-density lipoproteins (HDL) play a crucial role in the pathology of Alzheimer's disease and vascular dementia, exchanging their protein and lipid components between the brain, cerebrospinal fluid, and vascular cells to impact brain amyloid metabolism and atherosclerosis. Modifications of HDL particles have potential diagnostic and therapeutic implications for brain vascular and neurodegenerative diseases.
High-density lipoproteins (HDLs) are complex, heterogenous lipoprotein particles, consisting of a large family of apolipoproteins, formed in subspecies of distinct shapes, sizes, and functions and are synthesized in both the brain and the periphery. HDL apolipoproteins are important determinants of Alzheimer's disease (AD) pathology and vascular dementia, having both central and peripheral effects on brain amyloid-beta (A beta) accumulation and vascular functions, however, the extent to which HDL particles (HLD-P) can exchange their protein and lipid components between the central nervous system (CNS) and the systemic circulation remains unclear. In this review, we delineate how HDL's structure and composition enable exchange between the brain, cerebrospinal fluid (CSF) compartment, and vascular cells that ultimately affect brain amyloid metabolism and atherosclerosis. Accordingly, we then elucidate how modifications of HDL-P have diagnostic and therapeutic potential for brain vascular and neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据